CELL INTELLIGENCE · 肿瘤细胞治疗研究

下一代基于抗体的癌症治疗：抗体-药物偶联物和双特异性抗体在血液系统恶性肿瘤和实体瘤中的应用

Next-generation antibody-based therapeutics in cancer: antibody-drug conjugates bispecific antibodies across hematologic malignancies and solid tumors

平行处理 T 细胞与 NK 细胞以增强体内 CAR-T 细胞对血液肿瘤和实体瘤的活性

Parallel processing of T cells and natural killer cells to enhance in vivoCAR T cell activity against blood and solid cancers.

本研究鼓励优化利用白细胞单采产物。通过将废弃的 PBMC 回收为 NK 细胞，可有效增强 CAR-T 细胞疗法，改善肿瘤清除率和生存率。

靶向 PIM2 通过促进 CD8 T 细胞的效应功能和持久性增强抗肿瘤免疫

Targeting PIM2 improves antitumor immunity through promoting effector function and persistence of CD8 T cells.

探索肿瘤中的 SLAMF5/CD84：推进肿瘤免疫学前沿

Exploring SLAMF5/CD84 in Cancer: Advancing the Frontiers of Tumor Immunology.

血液系统恶性肿瘤患者 CAR-T 细胞治疗后的第二原发恶性肿瘤

Second primary malignancies following CAR T-cell therapy in patients with hematologic malignancies.

mRNA 递送在肿瘤免疫治疗中的应用

Applications of mRNA Delivery in Cancer Immunotherapy.

RORing CAR-T 细胞在实体瘤与血液肿瘤中：相同却不同

RORing CAR T Cells in Solid and Hematologic Cancers: Same but Different.

ROR1 特异性 CAR-T 细胞治疗晚期血液系统与上皮恶性肿瘤的 I 期研究

Phase I Study of ROR1-Specific CAR-T Cells in Advanced Hematopoietic and Epithelial Malignancies.

ROR1 CAR-T 细胞在大多数患者中耐受良好。

基于水凝胶共递送 CAR-T 细胞和线粒体自噬激动剂提高三阴性乳腺癌免疫治疗疗效

Improved Efficacy of Triple-Negative Breast Cancer Immunotherapy via Hydrogel-Based Co-Delivery of CAR-T Cells and Mitophagy Agonist.

各种成人白血病和淋巴瘤类型中 ROR1 水平的肿瘤评估

Tumour assessment of ROR1 levels in various adult leukaemia and lymphoma types.